HSL-AD Molecular Pathology
HSL-AD offers the Zytovision VisionArray HPV Genotyping Assay, the Prosigna Breast Cancer Assay and, in partnership, a next-generation sequencing service for routine cancer diagnostics and oncology clinical trials.
HSL-AD participates in external quality assurance (EQA) across various modules through UK NEQAS ICC & ISH, NordiQC, and GenQA. For tests not covered by conventional EQA schemes within the previous 12 months, an alternative approach to EQA is implemented to ensure ongoing quality assessment.
Molecular tests
| Test name |
|---|
| EGFR mutation |
| Zytovision VisionArray HPV Genotyping Assay |
| Prosigna Breast Cancer Assay |
Next-generation sequencing (NGS) service
HSL-AD partners with Sarah Cannon Molecular Diagnostics to provide a next-generation sequencing service for routine cancer diagnostics and oncology clinical trials.
Tests available include:
- MGP-4: An NGS-based test, looking at tumour derived DNA and/or RNA, to help guide targeted therapy use
- MGP-5: An NGS-based test, looking at tumour derived DNA, to help guide PARP inhibitor use
- Rapid-turnaround tests, looking at selected biomarkers only to help guide key personalised therapy options
- MSI and MLH-1 promoter methylation analysis
- Endopredict test (Myriad Genetics)
Contact details:
Sarah Cannon Molecular Diagnostics
Ground Floor, Shropshire House,
1 Capper Street
London, WC1E 6JA.
Tel: 020 3794 1920
Email: info@sarahcannon-md.co.uk
www.sarahcannon-md.co.uk